Introduction
MicroRNAs (miRNAs) are short, non-coding RNAs that regulate gene expression at the post-transcriptional level. In recent years, miRNAs have been shown to be integral in regulating not just normal homeostasis, development and physiology but also disease pathogenesis in terms of initiation, progression or resolution of the disease (Breving and Esquela-Kerscher 2010; Ding et al. 2009 ). According to miRBase version 21, there are more than 2500 annotated human miRNAs that are each predicted to regulate many mRNAs, and each mRNA can be targeted by a large number of different miRNAs (Breving and Esquela-Kerscher 2010; Fromm et al. 2015; Griffiths-Jones et al. 2008) . Importantly, most miRNAs are evolutionarily conserved, making the translation of findings from preclinical models more likely than some other molecular targets. These fundamental characteristics allow miRNAs to serve as potential biomarkers of disease progression and targets for therapeutic intervention.
MiRNAs are expressed from genomic DNA and processed in multiple steps before becoming ~22 nucleotide mature miRNAs (Fig. 1) . First, miRNAs are transcribed by RNA polymerase II and can originate from discrete miRNA-coding genes or from within introns of proteincoding genes (deemed "miRtrons") (Marco et al. 2013 ). Many diverse transcriptional regulators have been shown to contribute to miRNA expression including HIF1α, SMADs, p53, MYC, NF-κB and CREB (Wang et al. 2010c ). After Abstract Organ damage and resulting pathologies often involve multiple deregulated pathways. MicroRNAs (miRNAs) are short, non-coding RNAs that regulate a multitude of genes at the post-transcriptional level. Since their discovery over two decades ago, miRNAs have been established as key players in the molecular mechanisms of mammalian biology including the maintenance of normal homeostasis and the regulation of disease pathogenesis. In recent years, there has been substantial progress in innovative techniques to measure miRNAs along with advances in targeted delivery of agents modulating their expression. This has expanded the scope of miRNAs from being important mediators of cell signaling to becoming viable quantitative biomarkers and therapeutic targets. Currently, miRNA therapeutics are in clinical trials for multiple disease areas and vast numbers of patents have been filed for miRNAs involved in various pathological states. In this review, we summarize miRNAs involved in organ injury and repair, specifically with regard to organs that are the most susceptible to injury: the liver, heart and kidney. In addition, we review the current state of knowledge on miRNA biology, miRNA biomarkers and nucleotide-based therapeutics transcription, long stem-loop structures, called primary miRNAs (pri-miRNAs), undergo cleavage in the nucleus by an RNase-III-type enzyme, Drosha, to form 60-to-70-nucleotide precursor miRNAs (pre-miRNAs). Alternatively, miRtrons can bypass Drosha and form pre-miRNAs directly through spliceosome-mediated processing (Ruby et al. 2007 ). The Ran GTPase Exportin-5 complex then shuttles all pre-miRNAs through nuclear pore complexes into the cytosol. Pre-miRNAs are further processed by Dicer to generate miRNA duplexes. Then, miRNA duplexes will dissociate with the help of Argonaute 2 and passenger strands may degrade while the guide strands can remain active. Mature miRNAs then form the RNA-induced silencing complex (RISC), which include additional proteins necessary for Fig. 1 MiRNA expression, processing and function are highly organized. MicroRNA biogenesis begins with transcription of genomic DNA by RNA polymerase II and can be mediated by many common transcription factors. Often, large RNA stem-loop structures, called pri-miRNAs, are formed directly. Drosha then cleaves pri-miRNAs to form intermediate stem-loop structures, called pre-miRNAs. Alternatively, pre-miRNAs can form through an intermediate, called a "miRtron" from splicing of mRNA. Exportin 5 (XPO5) then transports pre-miRNAs through nuclear pore complexes (NPC) into the cytosol. In the cytosol, Dicer cleaves pre-miRNAs to form microRNA duplexes. Argonaute 2 (AGO2) then mediates the dissociation of the miRNA duplex to form two mature miRNAs. These two miRNAs are deemed "5p" or "3p" depending on whether they originate from the 5′ or 3′ end of the pre-miRNA, respectively. Depending on the context or specific miRNA, mature miRNAs will either assemble within RNA-induced silencing complexes (RISC), degrade or may reenter the nucleus via Importin 8 (IPO8) to regulate transcription. After RISC assembly, miRNAs can bind to mRNAs with their complementary seed region to the 3′ untranslated region (UTR), 5′ UTR or the open reading frame (ORF). MiRNAs then regulate protein production either by promoting mRNA degradation or by inhibiting translation mRNA silencing activity (Su et al. 2009) . Mature miRNAs will canonically match their "seed regions" (nucleotides 2 through 8 on the 5′ end of the miRNA) to a complementary region on the 3′ untranslated region (UTR) of a target mRNA (Ding et al. 2009 ). However, evidence has emerged that miRNAs can bind to 5′ UTRs and within the mRNA coding sequence (Ørom et al. 2008; Brümmer and Hausser 2014) . These interactions promote mRNA degradation or inhibit protein synthesis and are responsible for regulating gene expression (Huntzinger and Izaurralde 2011) . In addition, though most miRNAs act in the cytosol to regulate translation some mature miRNAs can reenter the nucleus to regulate transcription, miRNA expression and RNA processing (Wei et al. 2014; Tang et al. 2012) .
When organs experience injury or disease, affected cells may release specific miRNAs into circulation and miRNA biomarkers can be detected in the blood, urine and various other body fluids (Saikumar et al. 2014) . MiRNA biomarkers are remarkably stable due to packaging within microvesicles and/or binding to RISC protein components or high-density lipoproteins (Harrill et al. 2016) . In addition, nucleotide-based therapeutics have been developed that can either mimic or inhibit miRNA expression in vivo. MiRNA therapeutics can resist degradation in systemic circulation due to modifications to the nucleotide backbone or by being packaged within microvesicles before dosing (van Rooij et al. 2012; Wang et al. 2015; Beavers et al. 2015) . Clinical trials are currently underway for a miR-122 inhibitor to treat hepatitis C virus (HCV) (Gebert et al. 2014 ), a miR-21 inhibitor to treat Alport nephropathy (clinicaltrials.gov. 2016) and a miR-34a mimic to treat liver cancer (Bouchie 2013) . These aspects highlight the transformative potential of miRNAs as mechanistic biomarkers and therapeutic targets in translational medicine. In this review, we discuss the role of miRNAs in organ damage and repair with a particular focus on the liver, heart and kidney, which are organs that are most susceptible to injury.
MiRNAs in liver injury and repair

MiRNAs in liver injury
Drug-induced liver injury (DILI) accounts for more than half of all cases of acute liver failure in many Western countries and acetaminophen (APAP) overdose is a major cause in the United States (Lee 2008) . DILI is also a major reason for attrition during drug development and is one of the main causes of withdrawing drugs from the market (Lee 2003) . Other causes of liver injury include chronic viral hepatitis C (HCV) and non-alcoholic fatty liver disease (NAFLD), which are two of the leading causes of chronic liver disease worldwide (de Alwis and Day 2008; Mohd Hanafiah et al. 2013) . The liver encounters toxic stress due to its anatomical location and first-pass metabolism and biotransformation that results in generation of toxic reactive metabolites. Current methods of detecting liver damage include measuring aminotransferases, such as alanine aminotransferase (ALT) and total bilirubin in the blood. However, these methods lack sensitivity and specificity, especially with regard to early detection and prognoses of liver disease, and other factors can affect the quantities of these markers in the blood (Ozer et al. 2008) . Therefore, miRNAs have been explored as biomarkers and as mediators in the mechanisms of pathogenesis for a number of these liver ailments.
MiR-122
MiR-122 is the most abundant miRNA in the liver and has been implicated in basic liver physiology, disease and regeneration (Bandiera et al. 2015) . MiR-122 has been shown to be expressed up to 100,000-times higher in the normal liver compared to other tissues such as brain, heart, kidney and lung (Laterza et al. 2009 ). MiR-122 knockout mice were shown to develop steatohepatitis, fibrosis and hepatocellular carcinoma, which indicates the protective role of miR-122 in pathogenesis of liver disease (Tsai et al. 2012; Hsu et al. 2012) . Furthermore, miR-122 has emerged as a promising biomarker of liver damage and can be measured in blood (Fig. 2) . MiR-122 has been demonstrated to be more sensitive and with a greater dynamic range than ALT in both animals and humans. In mice subjected to APAP-induced liver injury, miR-122 was decreased in liver tissue but highly increased in the plasma in a dosedependent manner (Wang et al. 2009 ). In humans with APAP-induced hepatotoxicity, miR-122 was significantly increased in the sera compared to healthy controls and has shown its utility to diagnose APAP toxicity in at least one clinical case (Starkey Lewis et al. 2011; Dear et al. 2014) .
Importantly, miR-122 upregulation in the blood is responsive to diverse etiologies of DILI. Specifically, miR-122 allowed for early detection of liver injury following exposure to alpha-naphthylisothiocyanate (Church et al. 2015; Yamaura et al. 2012) , methapyriline (Yamaura et al. 2012) , tri-chlorobromomethane (Laterza et al. 2009 ), carbon tetrachloride (CCl 4 ) (Laterza et al. 2009 ) and dioxin (Yoshioka et al. 2011 ). In addition, miR-122 has been used as a diagnostic biomarker in other disease settings including NAFLD (Miyaaki et al. 2014) , alcoholic liver disease (Bala 2012) and chronic HCV infection (Köberle et al. 2013; Meer et al. 2013) . In HCV, miR-122 was found to play a critical role in promoting the viral life cycle and when inhibited interferes with viral replication (Gebert et al. 2014 ). Thus, a miR-122 inhibitor, Miravirsen, is currently in clinical trials to treat HCV in human patients (Janssen et al. 2013) . Though many of the targets of miR-122 are currently unknown, miR-122 is clearly a critical miRNA in the liver and is promising to diagnose and treat liver diseases.
MiR-192
MiR-192 is highly enriched in the liver and elevated after injury, but it is also expressed highly in other tissues including small intestine, colon and kidney, which is different from the liver-specific miR-122 (Jenkins et al. 2012) . Following diverse etiologies of DILI in both animal and in human sera, miR-192 has been shown to track with miR-122 expression; however, miR-192 is generally not as highly expressed as miR-122 (Wang et al. 2009; Starkey Lewis 2011; Nagano et al. 2013; Krauskopf et al. 2015) . In addition, miR-192 and miR-122 were effective serum biomarkers of liver injury in rats that experienced acute liver transplantation rejection (Hu et al. 2013) . In a recent study, miR-192 was increased in the sera of humans with acute liver failure and in mice subjected to hepatic ischemia-reperfusion injury or liver injury induced by CCl 4 (Roy et al. 2016 ). In addition, miR-192 in sera was correlated with increasing liver damage. However, miR-192 was downregulated in liver tissues of mice and humans with liver injury. In a mouse hepatoma cell line, miR-192 was shown to target Zeb2, an anti-apoptotic gene, and increased susceptibility to oxidative stress (Roy et al. 2016 ).
MiR-125b
MiR-125b-5p was increased in the blood of patients with APAP overdose and HCV (Ward et al. 2014; Ninomiya et al. 2016) . Recently, miR-125b overexpression was MiR-122 is the most abundant miRNA in the liver and can increase or decrease in the liver tissue depending on the injury or disease. In diverse forms of liver injury and disease, miR-122 is secreted into the blood within small vesicles, dead cells or bound to RISC proteins or high-density lipoproteins. MiR-122 has been successfully utilized as a biomarker of various forms of liver injury and liver diseases such as HCV. Because of its involvement in HCV replication, miR-122 has also been successfully targeted pharmacologically with an inhibitor, Mirvirsen, which is currently in clinical trials shown to prevent liver injury and improve the survival of mice following APAP-induced liver failure (Yang et al. 2016) . To uncover the role of miR-125b in hepatocyte survival an unbiased screen of 302 miRNA mimics was performed using primary mouse hepatocytes. The cells were transfected with miRNA mimic library, subjected to APAP toxicity and analyzed for improvements in cell viability, where miR-125b was found as potential hit. Remarkably, administration of a hepatocyte-specific pri-miR-125b vector into mice before APAP overdose protected them from liver failure and death by targeting Kelch-like ECH-associated protein 1 (Keap1). Last, miR-125b was shown to be cytoprotective in human hepatocytes and was downregulated in biopsies from patients with acute liver failure (Yang et al. 2016) . This suggests that a miR-125b mimic may be therapeutically beneficial in patients with increased risk of liver failure.
MiR-34a
MiR-34a (Ferreira et al. 2014 ) is an established tumor suppressor implicated in promoting apoptosis and p21 expression in cancer cells (Yamakuchi and Ferlito 2008) . Though miR-34a is not liver-specific, it has been shown to be upregulated at the termination phase of liver regeneration in rats and inhibit proliferation by targeting inhibin αB and Met when overexpressed in rat hepatocytes (Chen et al. 2011 ). In addition, miR-34a has been shown to be significantly upregulated in animals and humans with non-alcoholic fatty liver disease (NAFLD) (Cheung et al. 2008; Castro et al. 2013) . In rat hepatocytes, miR34a overexpression increased apoptosis when challenged with ursodeoxycholic acid via directly targeting Sirtuin 1 (SIRT1), an NAD-dependent deacetylase for p53 (Castro et al. 2013) . In an in vivo study, miR-34a was shown to target SIRT1 and peroxisome proliferatoractivated receptor-α (PPARα), an essential modulator of lipid transport and metabolism (Ding et al. 2015) . Importantly, when injected with a miR-34a inhibitor, mice with NAFLD had less lipid accumulation and improvements in levels of steatosis (Ding et al. 2015) . Taken together, miR-34a is dysregulated in liver disease and may be targeted therapeutically to promote hepatocyte survival and limit steatosis.
MiRNAs in liver development and regeneration
Despite the liver's vulnerability to toxic insult, it is also the one mammalian organ that is capable of fully regenerating to achieve baseline size and function after acute or chronic injury (Michalopoulos and DeFrances 1997) . Normally, hepatocytes are highly differentiated and quiescent and will only enter the cell cycle once initiated by ischemia, toxic exposure or infection. Interestingly, mice with hepatocyte-specific Dicer knockout exhibit normal development and hepatic function at birth, suggesting the absence of mature miRNAs does not greatly affect liver development (Hand et al. 2009 ). However, within 4 months after birth these mice experience progressive liver damage, decreased function and aberrant hepatocyte proliferation and apoptosis (Hand et al. 2009 ). In addition, these mice were shown to have deficiencies in correct liver zonation, metabolic pathways and tumor suppression (Sekine et al. 2009a, b) . This suggests miRNAs are critical in basic liver function. Furthermore, specific miRNAs have been found that regulate processes of liver regeneration as well as the response toxic stress as will be discussed below (Table 1) . 
MiR-21
MiR-21 is among the most upregulated miRNAs during liver regeneration. Previously, miR-21 has been identified as an onco-miRNA that has multiple targets that normally inhibit proliferation. These targets include phosphatase and tensin homolog (PTEN), B cell translocation gene 2 (BTG2) and Ras homolog gene family member B (RhoB) (Yan-nan et al. 2014; Marquez et al. 2010; Song et al. 2010; Ng et al. 2012) . Therefore, when miR-21-specific antisense oligonucleotides were injected into mice following two-thirds hepatectomy, early liver regeneration was impaired because of a decrease in hepatocyte proliferation (Ng et al. 2012) . In this study, miR-21 was found to target RhoB and increase Akt and mammalian target of rapamycin (mTOR) signaling during early regeneration, which increased global translation in the cell via increased eukaryotic initiation factor (eIF)-4F activation. Also, upregulation of miR-21 increased cell cycle progression through G1 to S phase via accelerated translation of cyclin D1 mRNA (Ng et al. 2012) . A later study showed miR-21 was upregulated during in vitro hepatocyte proliferation and also targeted PTEN to enhance PI3 K/Akt activity (Yan-nan et al. 2014) . Interestingly, another study showed that deoxycholic acid (DCA)-a toxic bile acid that may lead to NAFLD-inhibited miR-21 expression in rats. When miR-21 was overexpressed in hepatocytes in vitro DCA-induced cell death was reduced (Rodrigues et al. 2015) . Overall, evidence suggests that miR-21 promotes liver regeneration and may protect from pathological liver diseases such as NAFLD.
MiRNAs in heart injury and repair
MiRNAs in heart injury
Many drugs and environmental chemicals are known to induce cardiotoxicity specifically by targeting cardiomyocytes and can contribute to the development of coronary heart disease (Kang 2001 ). Cardiotoxicity is a major obstacle to drug development largely because of the failure to predict it in preclinical studies (Qureshi et al. 2011) . Currently, pre-clinical and clinical cardiotoxicity biomarkers include measuring the electrical efficiency of the heart using electrocardiography, visualizing the heart with echocardiograms and hERG assays to assess QT prolongation. In addition, methods for assessing cardiac dysfunction include measuring cardiac troponins or performing endomyocardial biopsies, which are invasive (Koturbash et al. 2015) . Therefore, miRNAs have been studied as being more sensitive, specific and stable biomarkers of heart disease ( Table 2 ). In addition, many groups have looked at miRNAs that respond to direct cardiac injury and are involved in mechanisms of cardiomyocyte cell death.
MiR-34a
In a mouse model of chronic cardiotoxicity using doxorubicin, miRNA sequencing identified that miR-34a was the only miRNA upregulated across five time points and showed higher expression with increasing doses of doxorubicin (Desai et al. 2014) . In a different study, miR-34a was increased in the serum exosomes of patients who Corsten et al. (2010) suffered myocardial infarction (MI) and developed heart failure within 1 year, showing its potential as a prognostic biomarker (Matsumoto et al. 2013 ). In addition, miR34a has been implicated in aging-associated cardiomyocyte cell death and when inhibited in mice after MI reduced cell death and improved recovery of cardiac function (Boon et al. 2013) . Taken together, miR-34a acts similarly in the heart as was previously discussed in the liver by promoting cell death and tissue dysfunction.
MiR-208a
MiR-208a is a cardiac-specific miRNA that is generated from the intronic region of the gene that codes for a major protein that regulates myocardial contractility in the adult heart, α-myosin heavy chain (α-MHC) (Oliveira-Carvalho et al. 2013 ). MiR-208a has been shown to regulate critical cardiac transcription factors and is required for proper cardiac function (Callis et al. 2009 ). Specifically, overexpression of miR-208a resulted in increased α-MHC expression and was associated with arrhythmias, fibrosis and hypertrophy in mice (Callis et al. 2009 ). Following isoproterenolinduced cardiac injury in rats, miR-208a was shown to have stable upregulation in plasma and was superior to cardiac troponins in indicating injury (Liu et al. 2014; Nishimura et al. 2015) . MiR-208a was also increased in the human heart tissue of patients who died from MI (Bostjancic et al. 2009 ). Importantly, miR-208a was upregulated in plasma and exhibited a greater sensitivity than cardiac troponins in patients following MI (Wang et al. 2010a ). As such, miR-208a has also been evaluated as a possible therapeutic target for heart injury. In one study, inhibiting miR-208a before doxorubicin treatment prevented cardiomyocyte apoptosis and improved cardiac function as determined by echocardiography (Tony et al. 2015) . In addition, in a rat model of congestive heart failure, miR-208a inhibition prevented pathological cardiac remodeling and improved cardiac function and survival (Montgomery et al. 2011) .
MiRNAs in heart development and regeneration
During development, the heart increases in size due to proliferation of cardiomyocytes. Despite some limited renewal throughout life, mammalian cardiomyocytes generally exit the cell cycle after birth and any further increase in heart size is due to enlargement of existing cells (Bergmann et al. 2009 ). The failure of cardiomyocytes to proliferate after injury can lead to persistent thinning of the myocardial wall, an expansion of cardiac fibroblasts that can lead to fibrosis and an overall decrease in cardiac function. MiRNAs have been shown to be necessary for proper heart development and cardiac function. Previously, mice with cardiac progenitor cell-specific Dicer deletion were shown to be embryonically lethal due to malfunctions in ventricular myocardium development, outflow tract morphogenesis and chamber septation (Saxena and Tabin 2010; Zhao et al. 2007 ). Likewise, 3-week-old juveniles with myocardiumspecific, tamoxifen-inducible Dicer knockout resulted in ventricular remodeling and premature death within 1 week. Also using these mice, it was shown that inducing Dicer knockout in adults led to severe hypertrophy, myofiber disarray and ventricular fibrosis (da Costa Martins et al. 2008) . Recently, many miRNAs have been identified as being critical for the normal development of the heart and in enhancing processes of repair after injury.
MiR-15 family
In mice, there is short period (<7 days) after birth when the heart can sustain ischemic injury and cardiomyocytes will proliferate to facilitate full regeneration; however, these regeneration mechanisms are silenced after this period (Porrello et al. 2011a ). Previously, the miR-15 family was shown to help regulate this process (Fig. 3) . The miR-15 family is composed of six members (including miR-15a, miR-15b, miR-16-1, miR-16-2, miR-195 and miR-497) that all have the same seed sequence. Interestingly, the miR-15 family generally, and miR-195 specifically, are among the most highly expressed miRNAs immediately after the postnatal period when mice lose the ability to regenerate the heart. Overexpression of miR-195 has been shown to promote even earlier premature cardiomyocyte cell cycle withdrawal by targeting checkpoint kinase 1 (Chek1), which regulates the progression through G2/M and spindle assembly checkpoints in the cell cycle (Porrello et al. 2011b ). Conversely, inhibition of miR-15b and miR-16 prolonged the postnatal regeneration period by increasing the expression of Chek1 (Porrello et al. 2013 ). In addition, the miR-15 family is highly upregulated after MI and was shown to promote apoptosis by targeting B cell lymphoma 2 (Bcl-2) and led to mitochondrial dysfunction by targeting ADP-ribosylation factor-like protein 2 (Arl2). Impressively, using anti-miRs complementary to the miR-15 family was able to protect adult mice and pigs from MI (Hullinger et al. 2012 ).
miR-17~92 cluster
Identified as the first onco-miRNA ("oncomiR-1"), the miR-17~92 cluster has been implicated in promoting cardiac differentiation and proliferation ( Fig. 3 ) (Mogilyansky and Rigoutsos 2013). This polycistronic cluster encodes six mature miRNAs (including miR-17, miR18a, miR-19a, miR-19b-1, miR-20a and miR-92-1), all of which are expressed differentially due to selective posttranscriptional processing mechanisms (Du et al. 2015) .
Using miR-17~92 knockout mice and in vitro knockdown strategies, the cluster was shown to target cardiac progenitor genes and promoted proper myocardial differentiation (Wang et al. 2010b ). Interestingly, cardiac-specific miR-17~92 knockout mice were shown to have smaller hearts due to a decrease in total cardiomyocytes, but most mice survived until adulthood despite decreased cardiac function (Chen et al. 2013 ). Conversely, cardiac-specific miR-17~92 transgenic mice had increased postnatal cardiomyocyte proliferation through direct PTEN suppression that resulted in larger hearts as well as cardiomyocyte proliferation into adulthood. Importantly, transgenic mice were protected from MI as shown by echocardiogram and increased cardiomyocyte proliferation (Chen et al. 2013 ).
miR-99/100 and Let-7a/c
Unlike mammals, many lower vertebrates including amphibians and fish retain the ability of cardiac regeneration throughout their entire lives (Oberpriller and Oberpriller 1974; Poss et al. 2002) . Specifically, adult zebrafish can sustain an amputation of up to 20% of the ventricle and the remaining cardiomyocytes will still dedifferentiate, proliferate and redifferentiate to completely regenerate the heart (Poss et al. 2002; Jopling et al. 2010) . Some groups have postulated that this ability may still be present in mammals and active during development but is somehow silenced in adulthood. A recent study explored this concept further by analyzing miRNAs in regenerating zebrafish hearts post-amputation Fig. 3 Diverse approaches have been developed using miRNAs that can promote heart regeneration. Cardiomyocytes (CMs) may be the target of injury from drugs, environmental chemicals or from myocardial infarction (MI). Following injury, cardiomyocytes die and do not normally recover. Many different approaches have been developed with specific miRNAs or combinations of miRNAs that promote cardiac regeneration and recovery (Aguirre et al. 2014) . They found two specific miRNA families, miR-99/100 and Let-7a/c, that were conserved in higher vertebrates and downregulated during zebrafish heart regeneration (Fig. 3) . These miRNAs were shown to target SMARCA5 and FNT-α which are key regulators of differentiation. In mice, however, miR-99/100 and Let7a/c levels increase and SMARCA5 and FNTα decrease during development, but do not change following induction of MI in adults. Incredibly, inhibiting miR-99/100 after MI was sufficient to induce dedifferentiation and proliferation of cardiomyocytes, reduce infarct size and improve cardiac function (Aguirre et al. 2014 ).
Combination of miRNAs
Instead of increasing proliferation of surviving cardiomyocytes after injury, some groups have focused on inducing cardiac fibroblasts or embryonic stem cells (ESCs) to become cardiomyocytes and injecting them into the injured areas of the heart. In this case, however, combinations of miRNAs have been examined that regulate cardiomyocyte differentiation. Specifically, a set of miRNAs deemed "miR combo" (including miR-1, miR-133, miR208a and miR-299) have been utilized due to their established roles in cardiac-specific development and function ( Fig. 3) (Jayawardena et al. 2012) . Previously, both MiR-1 and miR-133 were shown to be co-transcribed, specific to cardiac muscle and skeletal muscle and integral for promoting proper heart development (Zhao et al. 2005; Heidersbach et al. 2013; Liu et al. 2008) . Also, ESCs have been transfected with miR-1 and improved cardiac function when transplanted following MI (Glass and Singla 2011) . However, there is evidence of miR-1 and miR-133 having opposing functions in cardiomyocyte differentiation, suggesting they likely have different but perhaps complementary roles in cardiac functions (Ivey et al. 2008; Chen et al. 2006) . The other members of miR combo, MiR-208 and miR-499, are intronic miRNAs both within the α-and β-MHC primary transcript and have been shown to control MHC expression (Callis et al. 2009; van Rooij et al. 2009 ). Through empirical experimentation, miR combo was discovered to induce significant fibroblast reprogramming to cardiomyocytelike cells in vitro (Jayawardena et al. 2012) . Importantly, following MI and the subsequent injection of lentivirusencoding miR combo in mice, cardiac fibroblasts became positive for cardiomyocyte markers. Injection of miR-1 alone was sufficient to promote this cardiac fibroblasts reprogramming in vivo, but the addition of miR-133, 208 and 499-especially when JAK inhibitor was includedfurther improved these effects and resulted in improved cardiac function (Hodgkinson et al. 2015) .
MiRNAs in kidney injury and repair
MiRNAs in kidney injury
The kidney is a critical organ for the excretion of waste products from the body and, therefore, like the liver, is a main target of toxicity or ischemic insult. As a result, acute kidney injury (AKI) is growing as a major problem for clinicians around the world (Lameire et al. 2013) . In fact, a recent meta-analysis found that AKI occurred in one-in-five adults and one-in-three children worldwide who were hospitalized with acute illnesses (Susantitaphong et al. 2013) . AKI is believed to be increasing in part due to growth in the aging population and health events such as diabetes mellitus, cardiovascular disease, invasive surgeries, sepsis, chronic kidney disease (which predisposes people to AKI) and exposure to environmental toxicants and nephrotoxic drugs (Rewa and Bagshaw 2014) . Therefore, because no specific treatments have yet been developed to ameliorate AKI, miRNAs have been investigated that may have a role. Proximal tubulespecific Dicer knockout mice were shown to be protected from renal ischemia reperfusion injury (IRI), suggesting that mature miRNAs are critical in regulating pathways that mediate the response to kidney injury (Wei et al. 2010) . Many specific miRNAs have also been identified that regulate kidney injury and offer therapeutic benefits when modulated (Table 3) . Current methods of detecting AKI rely on non-specific and insensitive biomarkers such as serum creatinine (SCr) and blood urea nitrogen (BUN) (Waikar et al. 2012) . In 2008, FDA and European Medicines Agency qualified seven biomarkers for kidney toxicity in preclinical studies and the evaluation of these in humans is currently ongoing (Vaidya et al. 2010) . These studies provided compelling evidence that showed proteins excreted in the urine, such as kidney injury molecule-1 (KIM-1), outperform BUN and SCr and correlate with histopathology in the rats. This has prompted investigators to conduct additional discovery studies to identify miRNAs as sensitive biomarkers or potentially as companion biomarkers that can also provide mechanistic information regarding pathway dysregulation (Pavkovic and Vaidya 2016) .
MiR-21
MiR-21 is the most studied miRNA in kidney disease and is promising as both a biomarker and therapeutic target (Fig. 4) . Mice with miR-21 deletion or treated with miR-21 inhibitors after the induction of unilateral ureteral obstruction (UUO)-induced kidney injury were protected from fibrosis development (Chau et al. 2012) . In this study, miR-21 was shown to directly target PPARα and Mpv17 l, an inhibitor or reactive oxygen species (ROS) generation in the mitochondria, and, therefore, miR-21 knockout mice had increased lipid oxidation, higher activation of metabolic pathways and decreased ROS following injury. In a mouse model of Alport syndrome, a genetic disorder involving progressive fibrosis that results in end-stage renal failure in young adults, miR-21 inhibition significantly reduced the development of fibrosis (Gomez et al. 2015) . Because of these promising preclinical results, a miR-21 inhibitor, RG-012, is currently in Phase 2 clinical trials for this indication (clinicaltrials.gov. 2016). In addition, our lab was among the first to measure miR-21 in the urine supernatant in mice and patients following AKI (Saikumar et al. 2012) . Later, our lab was able to effectively differentiate AKI patients from healthy patients by measuring miR-21 combined with miR-200c, miR-423 and miR-4640 in urine (Ramachandran et al. 2013) . Since then, miR-21 has been found to be a reliable biomarker of drug-induced kidney injury (Pavkovic and Vaidya 2016) and fibrosis (Glowacki et al. 2013 ) and was associated with kidney injury from multiple chronic diseases including type 2 diabetes and IgA nephropathy (Zhong et al. 2013; Hennino et al. 2016 ).
Additional miRNA biomarkers for AKI
Investigators looking at miRNA biomarkers of AKI have focused largely on measuring changes in the urine, since the kidney's role is to produce urine and its collection is noninvasive. In addition, miRNAs are remarkably stable in this medium (Mall et al. 2013 ). Multiple groups have described urinary miRNA expression changes in preclinical rodent models and patients with drug-induced kidney injury (Pavkovic and Vaidya 2016) . In one study, male Wistar rats treated with a single dose of the nephrotoxicant cisplatin were shown to have a greater than 20-fold increase in 11 miRNAs in the urine-including miR-15, miR-16, miR-20a, miR-192, miR-193 and miR-210-over multiple time points (Pavkovic et al. 2014) . Another study using cisplatin in Sprague-Dawley rats found let-7 g-5p, miR-93, miR-191a and miR-192 significantly increased in the urine after injury (Kanki et al. 2014) . Though kidney biopsies are rarely acquired in the clinic, sequencing studies conducted on biopsies of human kidney allografts have suggested specific miRNAs that may be used as biomarkers of acute rejection. In a study comparing 12 acute rejection biopsies to 21 normal, six miRNAs were differentially regulated including miR-142-5p, miR-155 and miR-223 (all upregulated) and miR-10b, miR-30a-3p and let-7c (all downregulated) (Anglicheau et al. 2009 ). In a later study, several miRNAs including miR-21, miR-142-3p, miR-142-5p and the miR-506 cluster were significantly increased in allograft biopsies with tubulointerstitial fibrosis compared to normal while miR-30a, miR-30d and miR-30e were all significantly downregulated (Ben-Dov et al. 2012 ). Though more crossvalidation and translational studies are needed, these studies show the potential of miRNA biomarkers for AKI. 
MiRNAs in kidney development and regeneration
Following an episode of AKI the kidney has a remarkable ability to regenerate, though repeated injury or incomplete repair could lead to chronic kidney disease (Bonventre 2014) . During mammalian development, Six2-positive progenitor cells give rise to all of the diverse cell types that constitute the nephron (Kobayashi et al. 2008) . Previous studies in mice using Six2-specific Dicer ablation have shown that miRNAs are critical in regulating proper nephrogenesis (Nagalakshmi et al. 2011) . In addition, Six2-specific miR-17~92 knockout mice had decreased nephrogenesis and developed albuminuria and glomerulosclerosis by three months (Marrone et al. 2014) . Likewise, Dicer knockouts in other kidney cell subtypes have had differential effects on kidney function. For example, proximal tubule-specific Dicer knockout mice had no apparent effects on kidney function under normal conditions (Wei et al. 2010) . Conversely, when Dicer was knocked out in podocytes (cells that are essential in forming the glomerular filtration barrier), mice appeared to develop normally but rapidly acquired significant glomerular and tubular injury, proteinuria and died within 4 weeks after birth (Ho et al. 2008) . Ablating Dicer in juxtaglomerular cells (cells in the glomerulus that are responsible for renin synthesis and release) resulted in decreased cell number, renin signaling and lowered blood pressure (Sequeira-Lopez et al. 2010) . Taken together, miRNAs are clearly critical in development but knowledge about specific miRNAs that regulate processes of regeneration is limited. Compared to other organs discussed in this review, more is known about miRNAs that mediate kidney injury than about specific miRNAs involved in kidney repair. Nonetheless, some efforts have been initiated through temporal miRNA sequencing experiments following AKI to identify miRNAs that are elevated during periods of repair. Our lab recently conducted small RNA sequencing in mice subjected to folic acid-induced nephropathy and identified 108 miRNAs that were differentially regulated across seven time points (Pellegrini et al. 2015) . Using principal component analysis, we found that there were unique expression patterns of miRNAs in the injury phase versus the repair and fibrotic phases. In addition, at early time points following injury when repair processes are initiated (days 1 through 3), miR-18a and miR-132 were highly expressed throughout the renal cortex and in the injured tubules. Similar temporal expression patterns were seen in renal IRI and UUO models. Independent of our lab, a different miRNA sequencing experiment conducted on multiple early time points following induction of renal IRI Yin et al. (2010) identified miR-18a as possibly being involved in repair (Cui et al. 2016 ). Interestingly, in a different study miR-132 inhibition following UUO was shown to increase the number of proliferating proximal tubular cells and reduce the development of fibrosis, but inhibition of miR-132 in vitro resulted in less proliferation (Bijkerk et al. 2016) . In addition to these miRNAs, a recent study showed that miR-687 induced cell cycle progression by targeting PTEN following IRI in mice (Bhatt et al. 2015) . Interestingly, however, inhibiting miR-687 resulted in less tubular apoptosis and improved kidney function. Much more work must be conducted on kidney regeneration in general and how miRNAs specifically mediate these processes.
Other miRNAs involved organ injury and repair
In addition to the liver, heart and kidney, there is emerging evidence of miRNAs offering therapeutic potential in the injury and repair of other organs. For example, miRNAs have been identified that are associated with the injury and repair of lungs, skin and the central nervous system (Table 4) .
Future perspectives
The rapid growth in miRNA research has made clear that miRNAs are critical players in the molecular mechanisms of mammalian biology. There is ample evidence that miRNAs can serve as stable and specific biomarkers of various disease states and efficacious targets to manipulate therapeutically. As a result, there has been a surge of patent applications that is approaching 500 annually and there are many miRNA therapeutics in various stages of clinical development (Christopher et al. 2016) . Still, challenges exist in oligonucleotide therapeutic development and delivery. Because of the ability of miRNAs to regulate multiple pathways and their different functions depending on the tissue and context, identifying miRNAs that can be modulated efficaciously and safely in patients may be difficult. In addition, although different miRNA targeting strategies are being developed there are currently no examples of miRNA-specific oral therapeutics, and halflife and specificity remains an important issue. Nonetheless, chemically modified oligonucleotides and liposomal delivery methods have made enormous progress in recent years. Diverse strategies of therapeutic delivery include restoring miRNA function with mimics or overexpression vectors or inhibiting miRNAs with antisense oligonucleotides, vectors that express miRNA "sponges" or small molecule inhibitors that inhibit miRNA pathways (Li and Rana 2014) . Moreover, proprietary chemical modifications to nucleotide backbones have been developed that confer resistance to serum nucleases and have improved target-binding affinities. Taken together, manipulating miRNAs in human disease settings offers a promising path forward, particularly with regard to organ injury and repair.
